Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer

摘要

Disclosed is the use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicament to treat brain cancer. The compound is to be administered in a dosage from about 0.1 mg to about 150 mg per day and can be administered with a second active ingredient selected from hematopoietic growth factor, a cytokine, and an anti-cancer agent.